Iodide

Iodide

SCHEMBL5087284

CCCCCCCC[N+](CCC)(CCCCCCCC)CCCCCCCC.[I-]

nearest known ligand 0.88

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 4/20 0.81
ALDH1A1 P00352 1/20 0.77
TP53 P04637 1/20 0.77
CYP3A4 P08684 1/20 0.77
ALOX15 P16050 1/20 0.77
TSHR P16473 1/20 0.77
ALOX12 P18054 1/20 0.77
SMN1; SMN2 Q16637 1/20 0.77
HIF1A Q16665 1/20 0.77
HSD17B10 Q99714 1/20 0.77
SLC22A2 O15244 1/20 0.75
DNM1 Q05193 7/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL5088074 1.00 SLC22A1 (0.81) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Iodide SCHEMBL8438836 1.00 SLC22A1 (0.81) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Iodide SCHEMBL5087906 1.00 SLC22A1 (0.81) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Iodide SCHEMBL5084907 1.00 SLC22A1 (0.81) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Iodide SCHEMBL5087935 1.00 SLC22A1 (0.81) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Iodide SCHEMBL5091301 1.00 SLC22A1 (0.81) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Iodide SCHEMBL5092140 1.00 SLC22A1 (0.81) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Iodide SCHEMBL5091439 1.00 SLC22A1 (0.81) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Iodide SCHEMBL5086846 1.00 SLC22A1 (0.81) SLC22A1ALDH1A1TP53CYP3A4ALOX15
Iodide SCHEMBL5085196 1.00 SLC22A1 (0.81) SLC22A1ALDH1A1TP53CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214386-A1 Stability; easily separated from solution; surface treatment of catalyst with Group seven compound; reacting epoxide with carbon dioxide NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2008-09-04 US disclosed
WO-2008024026-A2 USE OF 9-OXOACRIDINE-10-ACETIC ACID, ITS SALTS AND ESTERS FOR THE TREATMENT, PROPHYLAXIS OR RELAPSE PREVENTION OF PROSTATE CANCER SURKOV KIRILL GENNADIEVICH (RU) 2008-02-28 WO disclosed
EP-1217011-B1 Process for producing an expoxidized polymer KURARAY CO (JP) 2005-10-12 EP disclosed
US-20050104042-A1 Process for the synthesis of amine ethers from secondary amino oxides CIBA SPECIALTY CHEMICALS CORP. 2005-05-19 US disclosed
EP-1463717-A2 PROCESS FOR THE SYNTHESIS OF AMINE ETHERS FROM SECONDARY AMINO OXIDES AND USES Ciba SC Holding AG (CH) 2004-10-06 EP disclosed
WO-2003045919-A2 PROCESS FOR THE SYNTHESIS OF AMINE ETHERS FROM SECONDARY AMINO OXIDES AND USES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2003-06-05 WO disclosed
US-6541575-B2 Epoxidation of polymer having olefinic carbon-carbon double in absence of alkali metal by adding aqueous solution of ammonium tungstate and/or tungstophosphoric acid and phosphoric acid, adding hydrogen peroxide and quternary ammonium salt KURARAY CO., LTD. (JP) 2003-04-01 US disclosed
US-20020082348-A1 Process for producing an epoxidized polymer KURARAY CO. LTD, (JP) 2002-06-27 US disclosed
EP-1217011-A1 Process for producing an expoxidized polymer KURARAY CO., LTD. (JP) 2002-06-26 EP disclosed
EP-0532861-B1 Method for producing a carbonic acid ester MITSUBISHI CHEM CORP (JP) 1996-05-01 EP disclosed
US-5227510-A 2-Hydroxypyridine Complexes MITSUBISHI KASEI CORPORATION (JP) 1993-07-13 US disclosed
EP-0532861-A1 Method for producing a carbonic acid ester Mitsubishi Chemical Corporation (JP) 1993-03-24 EP disclosed
EP-0149246-B1 OVERCOAT COMPOSITIONS CONTAINING NUCLEATING AGENTS AND ION-SELECTIVE ELECTRODES FOR CO2 DETERMINATIONS EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1990-02-28 EP disclosed
EP-0033707-B1 ELEMENT FOR LIQUID ANALYSIS HAVING INTERFERENT-REMOVAL ZONE AND METHOD FOR USING SAME EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1984-06-20 EP disclosed
EP-0030503-B1 BUFFER OVERCOAT FOR CO2 ION-SELECTIVE ELECTRODES EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1984-05-09 EP disclosed
US-4303408-A EXTRACTION ZONE BEFORE INDICATOR ZONE EASTMAN KODAK COMPANY (US) 1981-12-01 US disclosed
EP-0033707-A1 Element for liquid analysis having interferent-removal zone and method for using same EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1981-08-12 EP disclosed
EP-0030503-A1 Buffer overcoat for CO2 ion-selective electrodes EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1981-06-17 EP disclosed
US-4272328-A MULTILAYER, METALS, METAL HALIDES EASTMAN KODAK COMPANY (US) 1981-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050104042-A1 Process for the synthesis of amine ethers from secondary amino oxides AOC2, PPOX, DAO SLC22A1 4540/4885ALDH1A1 1566/4885TP53 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.